Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AdvaMed Urges Medicare Commission To Emphasize Devices As Opioid Alternatives

Executive Summary

In a statement to the Medicare Payment Advisory Commission, the medtech industry group bemoans the lack of consideration for medical device alternatives to opioids in treating pain management. The group says the commission should factor in such alternative treatments, per the SUPPORT Act, in their recommendations to Congress in March.

You may also be interested in...



Eight Products Enter US FDA’s Opioid Challenge

After spending the past six months receiving and reviewing hundreds of product applications, US FDA has decided to select eight promising devices and diagnostics to help tackle the opioid crisis.

President Signs Opioids Bill Calling For Alternative Tech, More Pain-Control Research

Industry groups praised newly enacted opioid-control legislation Oct. 24. The legislation will put more attention on existing medtech alternatives to addictive opioids and support research on new devices. Industry was positive about the new law, despite its expansion of sunshine reporting requirements that they oppose.

Massive Family Dollar Rat Infestation Leads To Multi-State Recall

The US FDA found more than 2,000 rats at an Arkansas Family Dollar distribution center, leadingto a six-state recall for products including feminine hygiene products, contact lens cleaners and face masks.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT124532

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel